Advertisement

What the Adult Nephrologist Should Know About Alport Syndrome

  • Clifford E. Kashtan
    Correspondence
    Address correspondence to Clifford E. Kashtan, MD, Department of Pediatrics, Division of Pediatric Nephrology, University of Minnesota Masonic Children's Hospital, 2450 Riverside Avenue, Academic Building – AC 201, Minneapolis, MN 55454.
    Affiliations
    Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN
    Search for articles by this author
      Recent trends in the diagnosis, treatment, and classification of collagen IV-associated kidney disease are likely to result in increasing numbers of people in adult nephrology practices who have a confirmed diagnosis of Alport syndrome. These trends include the increasing use of genetic testing in the diagnostic evaluation of people with hematuria, focal segmental glomerulosclerosis, and chronic kidney disease of unknown etiology; early treatment with inhibitors of the renin-angiotensin-aldosterone system to delay kidney failure; and application of an expanded definition of Alport syndrome based on genotype rather than phenotype. This commentary discusses these trends and their implications for the adult nephrologist.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Pokidysheva E.N.
        • Seeger H.
        • Pedchenko V.
        • et al.
        Collagen IVα345 dysfunction in glomerular basement membrane diseases. I. Discovery of a COL4A3 variant in familial Goodpasture's and Alport diseases.
        J Biol Chem. 2021; 296: 100590
        • Quinlan C.
        • Rheault M.N.
        Genetic basis of type IV collagen disorders of the kidney.
        Clin J Am Soc Nephrol. 2021; (16(7):1101-1109)
        • Kashtan C.E.
        Alport syndrome.
        in: Adam M.P. Ardinger H.H. Pagon R.A. Gene Reviews [Internet}. University of Washington, Seattle, Seatlle, WA2001: 1993-2021
        • Longo I.
        • Porcedda P.
        • Mari F.
        • et al.
        COL4A3/COL4A4 mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome.
        Kidney Int. 2002; 61: 1947-1956
        • Matthaiou A.
        • Poulli T.
        • Deltas C.
        Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by COL4A3 or COL4A4 mutations: a systemic review.
        Clin Kidney J. 2020; 13: 1025-1036
        • Kashtan C.E.
        • Ding J.
        • Garosi G.
        • et al.
        Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group.
        Kidney Int. 2018; 93: 1045-1051
        • Guthrie L.
        "Idiopathic" or congenital, hereditary and familial hematuria.
        Lancet. 1902; 1: 1243-1246
        • Hurst A.
        Hereditary familial congenital hemorrhagic nephritis occurring in sixteen individuals in three generations.
        Guy's Hosp Rec. 1923; 3: 368-370
        • Alport A.C.
        Hereditary familial congenital haemorrhagic nephritis.
        Br Med J. 1927; 1: 504-506
        • Flinter F.A.
        • Abbs S.
        • Bobrow M.
        Localization of the gene for classic Alport syndrome.
        Genomics. 1989; 4: 335-338
        • Barker D.F.
        • Hostikka S.L.
        • Zhou J.
        • et al.
        Identification of mutations in the COL4A5 collagen gene in Alport syndrome.
        Science. 1990; 248: 1224-1227
        • Boye E.
        • Mollet G.
        • Forestier L.
        • et al.
        Determination of the genomic structure of the COL4A4 gene and of novel mutations causing autosomal recessive Alport syndrome.
        Am J Hum Genet. 1998; 63: 1329-1340
        • Heidet L.
        • Arrondel C.
        • Forestier L.
        • et al.
        Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome.
        J Am Soc Nephrol. 2001; 12: 97-106
        • Jais J.P.
        • Knebelmann B.
        • Giatras I.
        • et al.
        X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males.
        J Am Soc Nephrol. 2000; 11: 649-657
        • Bekheirnia M.R.
        • Reed B.
        • Gregory M.C.
        • et al.
        Genotype-phenotype correlation in X-linked Alport syndrome.
        J Am Soc Nephrol. 2010; 21: 876-883
        • Zhang Y.
        • Böckhaus J.
        • Wang F.
        • et al.
        Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome.
        Pediatr Nephrol. 2021; 36: 2719-2730
        • Groopman E.E.
        • Marasa M.
        • Cameron-Christie S.
        • et al.
        Diagnostic utility of exome sequencing for kidney disease.
        N Engl J Med. 2019; 380: 142-151
        • Gregory M.C.
        • Terreros D.A.
        • Barker D.F.
        • Fain P.N.
        • Denison J.C.
        • Atkin C.L.
        Alport syndrome--clinical phenotypes, incidence, and pathology.
        Contrib Nephrol. 1996; 117: 1-28
        • Barker D.F.
        • Pruchno C.J.
        • Jiang X.
        • et al.
        A mutation causing Alport syndrome with tardive hearing loss is common in the western United States.
        Am J Hum Genet. 1996; 58: 1157-1165
        • Barker D.F.
        • Denison J.C.
        • Atkin C.L.
        • Gregory M.C.
        Common ancestry of three Ashkenazi-American families with Alport syndrome and COL4A5 R1677Q.
        Hum Genet. 1997; 99: 681-684
        • Żurowska A.M.
        • Bielska O.
        • Daca-Roszak P.
        • et al.
        Mild X-linked Alport syndrome due to the COL4A5 G624D variant originating in the Middle Ages is predominant in Central/East Europe and causes kidney failure in midlife.
        Kidney Int. 2021; 99: 1451-1458
        • Gast C.
        • Pengelly R.J.
        • Lyon M.
        • et al.
        Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis.
        Nephrol Dial Transpl. 2016; 31: 961-970
        • Deltas C.
        • Savva I.
        • Voskarides K.
        • Papazachariou L.
        • Pierides A.
        Carriers of autosomal recessive Alport syndrome with thin basement membrane nephropathy presenting as focal segmental glomerulosclerosis in later life.
        Nephron. 2015; 130: 271-280
        • Malone A.F.
        • Phelan P.J.
        • Hall G.
        • et al.
        Rare hereditary COL4A3/COL4A4 variants may be mistaken for familial focal segmental glomerulosclerosis.
        Kidney Int. 2014; 86: 1253-1259
        • Savige J.
        • Gregory M.
        • Gross O.
        • Kashtan C.
        • Ding J.
        • Flinter F.
        Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy.
        J Am Soc Nephrol. 2013; 24: 364-375
        • Kashtan C.E.
        • Ding J.
        • Gregory M.
        • et al.
        Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport syndrome Research Collaborative.
        Pediatr Nephrol. 2013; 28: 5-11
        • Kashtan C.E.
        • Gross O.
        Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020.
        Pediatr Nephrol. 2021; 36: 711-719
        • Kashtan C.E.
        • Gross O.
        Correction to: clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020.
        Pediatr Nephrol. 2021; 36: 731
        • Gross O.
        • Beirowski B.
        • Koepke M.L.
        • et al.
        Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.
        Kidney Int. 2003; 63: 438-446
        • Gross O.
        • Licht C.
        • Anders H.J.
        • et al.
        Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy.
        Kidney Int. 2012; 81: 494-501
        • Yamamura T.
        • Horinouchi T.
        • Nagano C.
        • et al.
        Genotype-phenotype correlation and the effects of treatment with angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome.
        Kidney Int. 2020; 98: 1605-1614
        • Temme J.
        • Peters F.
        • Lange K.
        • et al.
        Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations.
        Kidney Int. 2012; 81: 779-783
        • Kashtan C.
        Multidisciplinary management of Alport syndrome: current Perspectives.
        J Multidiscip Healthc. 2021; 14: 1169-1180
        • Weir M.R.
        • Chen D.C.
        • Ku E.
        Should renin-angiotensin system blockade Be Avoided in patients with declining kidney function?.
        Am J Kidney Dis. 2020; 76: 739-741
        • Chertow G.M.
        • Appel G.B.
        • Andreoli S.
        • et al.
        Study Design and Baseline Characteristics of the cardinal trial: a Phase 3 study of bardoxolone methyl in patients with Alport syndrome.
        Am J Nephrol. 2021; 52: 180-189
        • Mabillard H.
        • Sayer J.A.
        SGLT2 inhibitors - a potential treatment for Alport syndrome.
        Clin Sci (Lond). 2020; 134: 379-388
        • Wheeler D.C.
        • Toto R.D.
        • Stefánsson B.V.
        • et al.
        A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
        Kidney Int. 2021; 100: 215-224
        • Jais J.P.
        • Knebelmann B.
        • Giatras I.
        • et al.
        X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study.
        J Am Soc Nephrol. 2003; 14: 2603-2610
        • Yefet E.
        • Tovbin D.
        • Nachum Z.
        Pregnancy outcomes in patients with Alport syndrome.
        Arch Gynecol Obstet. 2016; 293: 739-747
        • Brunini F.
        • Zaina B.
        • Gianfreda D.
        • et al.
        Alport syndrome and pregnancy: a case series and literature review.
        Arch Gynecol Obstet. 2018; 297: 1421-1431
        • Crovetto F.
        • Moroni G.
        • Zaina B.
        • Acaia B.
        • Ossola M.W.
        • Fedele L.
        Pregnancy in women with Alport syndrome.
        Int Urol Nephrol. 2013; 45: 1223-1227
        • Hui D.
        • Hladunewich M.A.
        Chronic kidney disease and pregnancy.
        Obstet Gynecol. 2019; 133: 1182-1194
        • Piccoli G.B.
        • Attini R.
        • Vasario E.
        • et al.
        Pregnancy and chronic kidney disease: a challenge in all CKD stages.
        Clin J Am Soc Nephrol. 2010; 5: 844-855
        • Fu J.
        • Tomlinson G.
        • Feig D.S.
        Increased risk of major congenital malformations in early pregnancy use of angiotensin-converting-enzyme inhibitors and angiotensin-receptor-blockers: a meta-analysis.
        Diabetes Metab Res Rev. 2021; : e3453
        • Temme J.
        • Kramer A.
        • Jager K.J.
        • et al.
        Outcomes of male patients with Alport syndrome undergoing renal replacement therapy.
        Clin J Am Soc Nephrol. 2012; 7: 1969-1976
        • Gross O.
        • Weber M.
        • Fries J.W.
        • Müller G.A.
        Living donor kidney transplantation from relatives with mild urinary abnormalities in Alport syndrome: long-term risk, benefit and outcome.
        Nephrol Dial Transpl. 2009; 24: 1626-1630
        • Kashtan C.E.
        Renal transplantation in patients with Alport syndrome: patient selection, outcomes, and donor evaluation.
        Int J Nephrol Renovasc Dis. 2018; 11: 267-270
        • Brainwood D.
        • Kashtan C.
        • Gubler M.C.
        • Turner A.N.
        Targets of alloantibodies in Alport anti-glomerular basement membrane disease after renal transplantation.
        Kidney Int. 1998; 53: 762-766